The following resolution was passed at Calliditas Therapeutics AB (publ) (“Calliditas Therapeutics”) extraordinary shareholders’ meeting (the “EGM”) held today, on December 14, 2018, in Stockholm.
Long-term incentive program in the form of warrants
The EGM resolved, in accordance with the board of directors’ proposal, to adopt a long-term incentive program in the form of a not more than 1,160,000 warrants to employees and consultants within the Calliditas Therapeutics group, including a maximum of 25 participants. The participants are offered to acquire the warrants at market value according to the Black-Scholes valuation formulae. Each warrant entitles to subscription of one share in the company at a subscription price of SEK 74.30.
For further information, please contact:
Mikael Widell, Head of Communications
Telephone: +46 703-11 99 60
The information was submitted for publication, through the agency of the contact person set out above, at 16:15 pm CET on December 14, 2018.
Calliditas Therapeutics is a specialty pharmaceutical company based in Stockholm, Sweden, focused on developing high quality pharmaceutical products for patients with a significant unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization efforts. The company is focused on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics aims to take Nefecon through a global Phase 3 study to commercialization. The company is listed on Nasdaq Stockholm (ticker: CALTX). Visit www.calliditas.com for further information.